Przegląd Dermatologiczny

Full text

2/2026 vol. 113
Original article

Serum Chemerin Level as a Potential Biomarker of Early Cardiac Involvement in Patients with Psoriasis: a Case-Control Study

Mona Elradi 1
,
Ahmed Darwish 2
,
Heba Allah Mohamed Hoseiny 1

  1. Dermatology, Venereology and Andrology Department, Zagazig University Hospitals, Zagazig University, Egypt

  2. Cardiology Department, Zagazig University Hospitals, Zagazig University, Egypt

Dermatol Rev/Przegl Dermatol 2026, 113, 67–73

DOI: https://doi.org/10.5114/dr.2026.163265
Data publikacji online: 2026/07/31
Article file
Serum Chemerin.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Su X., Cheng Y., Zhang G., Wang B.: Chemerin in inflammatory diseases. Clin Chim Acta 2021, 517, 41-47.
  2. Nakajima H., Nakajima K., Nagano Y., Yamamoto M., Tarutani M., Takahashi M., et al.: Circulating level of chemerin is upregulated in psoriasis. J Dermatol Sci 2010, 60, 45-47.
  3. Kong S.M., Sun X.Y., Cui W.Y., Cao Y.C.: Chemerin exacerbates psoriasis by stimulating keratinocyte proliferation and cytokine production. Curr Med Sci 2023, 43, 399-408.
  4. Sun J.X., Zhang C., Cheng Z.B., Tang M.Y., Liu Y.Z., Jiang J.F., et al.: Chemerin in atherosclerosis. Clin Chim Acta 2021, 520, 8-15.
  5. Borsky P., Fiala Z., Andrys C., Beranek M., Hamakova K., Kremlacek J., et al.: C-reactive protein, chemerin, fetuin-A and osteopontin as predictors of cardiovascular risks in persons with psoriasis vulgaris. Physiol Res 2021, 70, 383-391.
  6. Aksu F., Caliskan M., Keles N., Erek Toprak A., Uzuncakmak T.K., Kostek O., et al.: Chemerin as a marker of subclinical cardiac involvement in psoriatic patients. Cardiol J 2017, 24, 276-283.
  7. Miller I.M., Ellervik C., Zarchi K., Ibler K.S., Vinding G.R., Knudsen K.M., et al.: The association of metabolic syndrome and psoriasis: a population- and hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2015, 29, 490-497.
  8. Schafer I., Hacker J., Rustenbach S.J., Radtke M., Franzke N., Augustin M.: Concordance of the Psoriasis Area and Severity Index and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010, 20, 62-67.
  9. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., et al.: Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015, 28, 1-39.e14.
  10. Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F., Dokainish H., Edvardsen T., et al.: Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016, 29, 277-314.
  11. Griffiths C.E., Barker J.N.: Pathogenesis and clinical features of psoriasis. Lancet 2007, 370, 263-271.
  12. Zwain A., Aldiwani M., Taqi H.: The association between psoriasis and cardiovascular diseases. Eur Cardiol 2021, 16, e19.
  13. Harden J.L., Lewis S.M., Pierson K.C., Suarez-Farinas M., Lentini T., Ortenzio F.S., et al.: CARD14 expression in dermal endothelial cells in psoriasis. PLoS One 2014, 9, e111255.
  14. Zachariae C., Skov L.: Obesity as a risk factor for psoriasis. J Eur Acad Dermatol Venereol 2020, 34, 915-916.
  15. Rodriguez-Zuniga M.J.M., Cortez-Franco F., Quijano-Gomero E.: Association of psoriasis and metabolic syndrome in Latin America: a systematic review and meta-analysis. Actas Dermosifiliogr 2017, 108, 326-334.
  16. Gerdes S., Zahl V.A., Weichenthal M., Mrowietz U.: Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010, 220, 38-43.
  17. Fan Z., Wang L., Jiang H., Lin Y., Wang Z.: Platelet dysfunction and its role in the pathogenesis of psoriasis. Dermatology 2021, 237, 56-65.
  18. Piaserico S., Papadavid E., Cecere A., Orlando G., Theodoropoulos K., Katsimbri P., et al.: Coronary microvascular dysfunction in asymptomatic patients with severe psoriasis. J Invest Dermatol 2023, 143, 1929-1936.e2.
  19. Federman D.G., Shelling M., Prodanovich S., Gunderson C.G., Kirsner R.S.: Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009, 160, 1-7.
  20. Garshick M.S., Ward N.L., Krueger J.G., Berger J.S.: Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol 2021, 77, 1670-1680.
  21. Mariani F., Roncucci L.: Chemerin/ChemR23 axis in inflammation onset and resolution. Inflamm Res 2015, 64, 85-95.
  22. Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M.: Scanning the immunopathogenesis of psoriasis. Int J Mol Sci 2018, 19, 179.
  23. Coban M., Tasli L., Turgut S., Ozkan S., Tunc Ata M., Akin F.: Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris. Ann Dermatol 2016, 28, 74-79.
  24. Gisondi P., Lora V., Bonauguri C., Russo A., Lippi G., Girolomoni G.: Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 2013, 168, 749-755.
  25. Helfer G., Wu Q.F.: Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol 2018, 238, R79-R94.
  26. Jialal I.: Chemerin levels in metabolic syndrome: a promising biomarker. Arch Physiol Biochem 2023, 129, 1009-1011.
  27. Tan L., Lu X., Danser A.H.J., Verdonk K.: The role of chemerin in metabolic and cardiovascular disease: a literature review of its physiology and pathology from a nutritional perspective. Nutrients 2023, 15, 2878.
  28. Ferland D.J., Watts S.W.: Chemerin: a comprehensive review elucidating the need for cardiovascular research. Pharmacol Res 2015, 99, 351-361.
  29. Inci S., Aksan G., Dogan P.: Chemerin as an independent predictor of cardiovascular event risk. Ther Adv Endocrinol Metab 2016, 7, 57-68.
  30. Aronis K.N., Sahin-Efe A., Chamberland J.P., Spiro 3rd A., Vokonas P., Mantzoros C.S.: Chemerin levels as predictor of acute coronary events: a case-control study nested within the Veterans Affairs Normative Aging Study. Metabolism 2014, 63, 760-766.
  31. Pletikosic I., Marasovic Krstulovic D., Bakovic D., Susilovic Grabovac Z., Tandara L., Martinovic Kaliterna D.: Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis. Sci Rep 2023, 13, 10371.
  32. Rokicka D., Bożek A., Wróbel M., Nowowiejska-Wiewióra A., Szymborska-Kajanek A., Stołtny T., et al.: Identification of silent myocardial ischemia in patients with long-term type 1 and type 2 diabetes. Int J Environ Res Public Health 2022, 19, 1420.
  33. Zhu T.Y., Li E.K., Tam L.S.: Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012, 2012, 714321.
  34. Bülbül Şen B., Ekiz Ö., Rifaioğlu E.N., Bülbül F., Şen T., Kızıldağ B., et al.: Assessment of subclinical left ventricular dysfunction in patients with psoriasis by speckle tracking echocardiography: a speckle tracking study. Int J Dermatol 2016, 55, 158-164.
  35. Simsek H., Sahin M., Akyol A., Akdag S., Ozkol H.U., Gumrukcuoglu H.A., et al.: Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. ScientificWorldJ 2013, 2013, 901215.
  36. Dikbas O., Tosun M., Bes C., Tonuk S.B., Aksehirli O.Y., Soy M.: Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 2016, 19, 672-677.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Indeks osobowy
Share
without publication fees
without publication fees
Coverage in
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications